Bloomberg Technology

CRISPR Co-Founder Jennifer Doudna on Future of Biotech

Sixth Street Chief Science Adviser and Nobel laureate Jennifer Doudna, co-founder of the CRISPR genome editing technology 10 years ago, and Sixth Street Vice Chairman and Partner R. Martin Chavez join Emily Chang to discuss the future of CRISPR and its potential for commercialization.

Published

3 years ago

on

Sixth Street Chief Science Adviser and Nobel laureate Jennifer Doudna, co-founder of the CRISPR genome editing technology 10 years ago, and Sixth Street Vice Chairman and Partner R. Martin Chavez join Emily Chang to discuss the future of CRISPR and its potential for commercialization.

Related Topics:

2 Comments

  1. Bokmg Mdsak

    February 11, 2022 at 12:06 am

    33zdnx
    vor.ngo

    Reply

  2. Omar A.

    February 11, 2022 at 12:53 am

    Jennifer DouDNA

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version